Redox Control of Leukemia: From Molecular Mechanisms to Therapeutic Opportunities
Year: 2012
Type: review
Abstract: Reactive oxygen species (ROS) play both positive and negative roles in the proliferation and survival of a cell. This dual nature has been exploited by leukemia cells to promote growth, survival, and genomic instability—some of the hallmarks of the cancer phenotype. In addition to altered ROS levels, many antioxidants are dysregulated in leukemia cells. Together, the production of ROS and the expression and activity of antioxidant enzymes make up the primary redox control of leukemia cells. By manipulating this system, leukemia cells gain proliferative and survival advantages, even in the face of therapeutic insults. Standard treatment options have improved leukemia patient survival rates in recent years, although relapse and the development of resistance are persistent challenges. Therapies targeting the redox environment show promise for these cases. This review highlights the molecular mechanisms that control the redox milieu of leukemia cells. In particular, ROS production by the mitochondrial electron transport chain, NADPH oxidase, xanthine oxidoreductase, and cytochrome P450 will be addressed. Expression and activation of antioxidant enzymes such as superoxide dismutase, catalase, heme oxygenase, glutathione, thioredoxin, and peroxiredoxin are perturbed in leukemia cells, and the functional consequences of these molecular alterations will be described. Lastly, we delve into how these pathways can be potentially exploited therapeutically to improve treatment regimens and promote better outcomes for leukemia patients. Antioxid. Redox Signal. 18, 1349–1383. I. Introduction II. How Does ROS Affect Leukemia? A. Background on leukemia B. Leukemic oncogenes C. How do leukemic oncogenes control the redox environment? III. Mechanisms of ROS Production in Leukemia A. Mitochondrial respiration: a source of life and death for the leukemia cell B. NOX as a source of oncogene-induced ROS C. Metabolic/detoxification pathways and ROS production in leukemia IV. Cellular Antioxidants in Leukemia A. Nrf2: a master regulator of antioxidant transcription B. Enzymatic elimination of ROS 1. Superoxide dismutase 2. Catalase 3. Heme oxygenase 4. Glutathione 5. Thioredoxin 6. Peroxiredoxin V. ROS-Dependent Therapeutic Agents A. Standard-of-care chemotherapeutic agents and modulation of oxidative stress 1. Purine analogs: cytarabine and fludarabine 2. Mitotic inhibitor: vincristine 3. Anthracyclines B. Recently approved ROS-producing agents 1. Arsenic trioxide 2. Histone deacetylase inhibitors 3. Proteasome inhibitors C. Preclinical redox modifying compounds for the treatment of leukemia 1. Preclinical ROS inhibition a. NOX inhibitors b. Xanthine oxidoreductase inhibitors c. SOD and catalase delivery 2. Preclinical ROS induction a. HO-1 inhibitors (protoporphyrins) b. Trx pathway inhibitors c. Isothiocyanates d. Adaphostin e. Piperlongumine f. Parthenolide VI. Summary/Remarks
Source: Antioxidants and Redox Signaling
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: leukemia, reactive oxygen species, redox regulation, oxidative stress, antioxidant enzymes, Nrf2, NADPH oxidase, mitochondrial electron transport chain, xanthine oxidoreductase, cytochrome P450, superoxide dismutase, catalase, heme oxygenase, glutathione, thioredoxin, peroxiredoxin, leukemia relapse, drug resistance
Open Access status: green
OpenAlex ID: W2008085394
